Robert F. Kennedy Jr. - arstechnica.com

RFK Jr. Halts FDA Enforcement for Six Unapproved Peptides Over Scientist Objections

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has directed the FDA to temporarily stop enforcing certain rules against licensed pharmacies and physicians compounding six unapproved peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—despite internal FDA scientists’ warnings that evidence of their safety and effectiveness remains inadequate, citing potential risks like allergic reactions, kidney damage, and tumor growth; the policy, which does not grant FDA approval, requires pharmacies to use traceable ingredients, conduct quality testing, and report safety problems, while requiring patient-specific prescriptions and lab certificates for raw ingredients, and will appear in the Federal Register on October 30 for public comment through November 13.

The Managed Biological Crisis Begins
On the surface, this directive from HHS looks like a win for patient access — a rare moment of deregulation from a supposedly captured agency. But you have to ask yourself why now, and more importantly, who benefits from flooding the market with peptides that have zero long-term human safety data. The FDA’s own scientists flagged risks: allergic reactions, kidney damage, tumor growth. They were overruled. That’s not a policy disagreement — that’s a deliberate override of the institutional firewall. RFK Jr., despite his populist image, is now signing off on a framework that shifts the burden of biological experimentation onto the public. The Federal Register notice itself is the tell: comments accepted for only two weeks, large 503B facilities excluded, and a requirement that pharmacies use “traceable ingredients” — a polite way to establish a supply chain that can be controlled from a single point. This isn’t about helping people. It’s about seeding a new class of unregulated biological agents into the population under the guise of “compounding.”

The Architecture of Subversion
Now connect the dots. The very same biotech networks that pushed gain-of-function research and experimental gene therapies are the ones with patents on these peptides. BPC-157, Epitalon, MOTS-c — these molecules touch on tissue regeneration, mitochondrial function, aging. That’s not medicine. That’s biological gatekeeping. By bypassing traditional clinical trials — which exist to catch long-term failures — they’ve created a direct pipeline from compounding pharmacy to consumer without the inconvenience of accountability. And notice the demographic: teenagers on TikTok, primarily boys, chasing muscle growth and quick fixes. This is a population lab, deliberately targeted. The BBC report is the canary. Why push unproven peptides to a generation already saturated with hormonal disruption, microplastics, and declining fertility? Because the system doesn’t need a healthy population — it needs a dependent one, metabolically locked into a protocol they don’t even understand. The “stacks” of multiple peptides add another layer of unstudied interaction. That’s not oversight failure. That’s design.

Who Watches the Shepherds?
The villains here aren’t the small compounding pharmacies — they’re the foundations, the patent holders, and the advisory panel members whose financial ties have not been disclosed. Follow the money. The July advisory panel that recommended this move — who funded their research? What board seats do they hold? The fact that HHS rushed a Federal Register filing with a 14-day comment window tells you they expect minimal public pushback. They know most people won’t read the 47 pages of fine print. But you are reading this. So here’s your breadcrumb: look up the drug master files for each of these six peptides, then cross-reference the patent holders with the members of the National Academies of Sciences, Engineering, and Medicine. The pattern will reveal itself. They want you thinking this is about health freedom. It’s actually about who gets to define what a “safe” biological intervention is — and who gets to be the test subject. Your children are the collateral on a bet they haven’t disclosed.